Federal Register / Vol. 62, No. 203 / Tuesday, October 21, 1997 / Notices 54639

Place: The Plantation, 9660 Dry Fork

Road, Harrison, Ohio 45020, telephone

513/367–5610.

Status: Open to the public, limited

only by the space available. The meeting

room accommodates approximately 50

people.

Background: Under a Memorandum

of Understanding (MOU) signed in

December 1990 with DOE and replaced

by an MOU signed in 1996, the

Department of Health and Human

Services (HHS) was given the

responsibility and resources for

conducting analytic epidemiologic

investigations of residents of

communities in the vicinity of DOE

facilities, workers at DOE facilities, and

other persons potentially exposed to

radiation or to potential hazards from

non-nuclear energy production use.

HHS delegated program responsibility

to CDC.

In addition, an MOU was signed in

October 1990 and renewed in November

1992 between ATSDR and DOE. The

MOU delineates the responsibilities and

procedures for ATSDR’s public health

activities at DOE sites required under

sections 104, 105, 107, and 120 of the

Comprehensive Environmental

Response, Compensation, and Liability

Act (CERCLA or ‘‘Superfund’’). These

activities include health consultations

and public health assessments at DOE

sites listed on, or proposed for, the

Superfund National Priorities List and

at sites that are the subject of petitions

from the public; and other healthrelated activities such as epidemiologic

studies, health surveillance, exposure

and disease registries, health education,

substance-specific applied research,

emergency response, and preparation of

toxicological profiles.

Purpose: This subcommittee is

charged with providing advice and

recommendations to the Director, CDC,

and the Administrator, ATSDR,

regarding community, American Indian

Tribes, and labor concerns pertaining to

CDC’s and ATSDR’s public health

activities and research at this DOE site.

The purpose of this meeting is to

provide a forum for community,

American Indian Tribal, and labor

interaction and serve as a vehicle for

community concern to be expressed as

advice and recommendations to CDC

and ATSDR.

Matters To Be Discussed: Agenda

items include: presentations from the

National Center for Environmental

Health (NCEH) regarding current

activities, the National Institute for

Occupational Safety and Health and

ATSDR will provide updates on the

progress of current studies, and an

overview of the Fernald Health Effects

Subcommittee’s mission and activities

will be part of the evening session.

Agenda items are subject to change as

priorities dictate.

CONTACT PERSON FOR MORE INFORMATION:

Steven A. Adams, Radiation Studies

Branch, Division of Environmental

Hazards and Health Effects, NCEH, CDC,

4770 Buford Highway, NE. (M/S F–35),

Atlanta, Georgia 30341–3724, telephone

770/488–7040, FAX 770/488–7044.

Dated: October 15, 1997.

Nancy C. Hirsch,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–27792 Filed 10–20–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Committee for Injury

Prevention and Control: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting.

Name: Advisory Committee for Injury

Prevention and Control (ACIPC).

Time and Date: 1–4:30 p.m., November 18,

1997.

Place: Sheraton Washington Hotel, 2660

Woodley Road at Connecticut Avenue, NW,

Washington, DC 20008.

Status: Open to the public, limited only by

the space available.

Purpose: The Committee advises and

makes recommendations to the Secretary, the

Assistant Secretary for Health, and the

Director, CDC, regarding feasible goals for the

prevention and control of injury. The

Committee makes recommendations

regarding policies, strategies, objectives, and

priorities, and reviews progress toward injury

prevention and control. The Committee

provides advice on the appropriate balance

and mix of intramural and extramural

research, including laboratory research, and

provides guidance on intramural and

extramural scientific program matters, both

present and future, particularly from a longrange viewpoint. The Committee provides

second-level scientific and programmatic

review for applications for research grants,

cooperative agreements, and training grants

related to injury control and violence

prevention, and recommends approval of

projects that merit further consideration for

funding support. The Committee

recommends areas of research to be

supported by contracts and provides concept

review of program proposals and

announcements.

Matters To Be Discussed: The Science and

Program Review Work Group (SPRWG) will

meet to discuss a research grants update,

upcoming program announcements, and

related issues. Following the Work Group

meeting, the full Committee will meet to

discuss (1) Safe America Partnership

Council; (2) National Partnership Council

including Federal and corporate components;

(3) a report from SPRWG; and (4) status of

the Institute of Medicine study on injury

prevention and control.

Agenda items are subject to change as

priorities dictate.

Contact Person for more Information:

Mr. Thomas E. Blakeney, Executive

Secretary, ACIPC, National Center for

Injury Prevention and Control, CDC,

4770 Buford Highway, NE, M/S K61,

Atlanta, Georgia 30341–3724, telephone

770/488–1481.

Dated: October 15, 1997.

Nancy C. Hirsch,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–27786 Filed 10–20–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Dermatologic and Ophthalmic Drugs

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Dermatologic

and Ophthalmic Drugs Advisory

Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on FDA

regulatory issues.

Date and Time: The meeting will be

held on November 13 and 14, 1997, 8:30

a.m. to 5:30 p.m.

Location: Holiday Inn, Versailles

Ballrooms I and II, 8120 Wisconsin

Ave., Bethesda, MD.

Contact Person: Tracy Riley or Angie

Whitacre, Center for Drug Evaluation

and Research (HFD–21), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–5455, or

FDA Advisory Committee Information

Line, 1–800–741–8138 (301–443–0572

in the Washington, DC area), code

12534. Please call the Information Line

for up-to-date information on this

meeting.